Thermolysis of 2-(3-phenylsulfonylprop-1-ynyl)benzonitrile: an aza-Myers type cyclization to isoquinolines

Ming-Jung Wu,* Chi-Fong Lin, Shang-Hung Chen and Fang-Chen Lee

School of Chemistry, Kaohsiung Medical College, Kaohsiung, Taiwan

Received (in Cambridge, UK) 8th July 1999, Accepted 6th September 1999

Thermolysis of 2-(3-phenylsulfonylprop-1-ynyl)benzonitrile (3) in refluxing benzene containing cyclohexa-1,4diene and triethylamine gave isoquinolone 4 in 7% yield and compound 5 in 10% yield and 14% of the starting material was recovered. When this cyclization reaction was carried out under oxygen atmosphere, compound 4 was isolated in 14% yield and 20% of the starting benzonitrile 3 was recovered. Under refluxing carbon tetrachloride, cyclization of 3 gave the chloroisoquinoline 6 in 18% yield and 5 in 22% yield. The isolation of compounds 4 and 6 strongly suggests the formation of biradical 8 through a (Z)hexa-2,4,5-trienenitrile intermediate 7.

The mechanism of the formation of biradicals derived from enediyne antitumor antibiotics has attracted much attention due to their DNA-cleaving properties.¹ In 1972, Jones and Bergman reported the thermal cyclization of (Z)-hex-3-ene-1,5diynes to 1,4-didehydrobenzene diradicals.² This cyclization is considered to be the major mode of formation of biradical intermediates in enediyne antitumor antibiotics. In studies on the mechanism of the DNA-cleaving activity of the neocarzinostatin chromophore, Myers and co-workers reported the cyclization (Z)-hepta-1,2,4-trien-6-ynes to α ,3-didehydrotoluene.³ of Several potent DNA-cleaving agents have been developed based on Myers cyclization.^{4,5} A similar cyclization occurs in the thermolysis of alkynylcyclobuten-4-one in which a biradical containing aryl and phenoxyl radical centers is produced via an enyne-ketene, as described by Moore and Yerxa.⁶ An alternative pathway to enyne-ketenes was reported by Saito and coworkers, which involved the photochemical Wolff rearrangement of enynyl α-diazo ketones.⁷ Recently, efforts have been made to cycloaromatize a conjugated system involving heteroatoms.⁸ Among these studies, there are two reports that describe the cyclization of (Z)-hexa-2,4,5-trienenitrile systems. One failed to obtain the cyclization product and the other obtained aniline adducts through an unusual stabilized allylic radical addition to nitrile.9 In this communication, we report the first successful example to isolate isoquinoline derivatives by thermolysis of 2-(3-phenylsulfonylprop-1-ynyl)benzonitrile (3) under alkaline conditions.

The synthesis 2-(3-phenylsulfonylprop-1-ynyl)benzonitrile (3) is outlined in Scheme 1. 2-Iodobenzonitrile (1) was directly



Scheme 1 *Reagents and conditions*: i) HC=CCH₂SPh, Pd(PPh₃)₄, Et₂O, CuI, BuNH₂, 46%; ii) MCPBA, CH₂Cl₂, 76%.

coupled to propargyl phenyl sulfide using tetrakis(triphenylphosphine)palladium(0) as the catalyst in the presence of cuprous iodode and *n*-butylamine, to give 2-(3-phenylthioprop-1-ynyl)benzonitrile (**2**) in 46% yield. Oxidation of sulfide **2** with 3 equivalents of MCPBA gave compound **3** in 76% yield.





Scheme 2 Reagents and conditions: i cyclohexa-1,4-diene, benzene, Et_3N , reflux, 2.5 days, 4 (7%) and 5 (10%). ii) CCl_4 , reflux, 2 days, 6 (18%) and 5 (20%).

tetrachloride in the presence of Et_3N for two days, the 1chloroisoquinoline **6** was isolated in 18% yield along with compound **5** in 22% yield. The structure of compound **5** was unambiguously determined by X-ray crystallography. The isolation of compounds **4** and **6** strongly suggests the biradical intermediate **8** is the intermediate of this cyclization reaction. A rational explanation for the formation of compounds **4** and **6** is proposed (Scheme 3). Base-catalyzed isomerization of



Scheme 3

propargyl sulfone **3** gives allenyl sulfone **7** which is not isolable and subsequently undergoes a Myers-type cyclization to produce the biradical intermediate **8**. Trapping the σ -radical of **8** with molecular oxygen and the α -radical with cyclohexadiene gives compound **4**. On the other hand, trapping the σ -radical

J. Chem. Soc., Perkin Trans. 1, 1999, 2875–2876 2875

This journal is © The Royal Society of Chemistry 1999

of 8 with carbon tetrachloride and hydrogen abstraction by the α -radical possibly from triethylamine leads to 6. In order to examine our hypothesis for the formation of compound 4, a control experiment was carried out; treatment of 3 with Et₃N under refluxing benzene and cyclohexa-1,4-diene under oxygen atmosphere for 24 h. Compound 4 was isolated in 14% yield and 20% of the starting nitrile 3 was recovered. The increased amount of compound 4 isolated under these conditions supports our hypothesis. The mechanism for the formation of compound 5 is not clear at this stage. A possible pathway is proposed. In the base-catalyzed isomerization of propargyl sulfone to allenyl sulfone, a small amount of phenyl sulfonyl anion was produced *via* an E_i mechanism. The phenyl sulfonyl anion then added to the allenyl sulfone 7 *via* a 1,4-addition to give compound 5.

In conclusion, we have demonstrated the first successful example of thermal cyclization of the (Z)-hexa-2,4,5-trienenitrile system to form isoquinoline derivatives and proved that this cyclization involved a diradical intermediate. The discovery of this new method of biradical formation provides a valuable source for theoretical study of enediyne related systems and an opportunity to design new DNA-cleaving antitumor agents.

Acknowledgements

We thank the National Science Council of the Republic of China for financial support of this work.

Notes and references

- For selected reviews of enediyne chemistry, see: (a) J. W. Grissom, G. U. Gunawardena, D. Klingberg and D. Huang, *Tetrahedron*, 1996, **52**, 6453; (b) K. K. Wang, *Chem. Rev.*, 1996, **96**, 207; (c) K. C. Nicolaou, W.-M. Dai, S.-C. Tsai, V. Z. Estevez and W. Wrasidlo, *Science*, 1992, **256**, 1172; (d) K. C. Nicolaou and A. L. Smith, *Acc. Chem. Res.*, 1992, **25**, 497; (e) K. C. Nicolaou and W.-M. Dai, *Angew. Chem., Int. Ed. Engl.*, 1991, **30**, 1387.
- 2 R. R. Jones and R. G. Bergman, J. Am. Chem. Soc., 1972, 94, 660.
- 3 (a) A. G. Myers, P. S. Dragovich and E. Y. Kuo, J. Am. Chem. Soc., 1992, 114, 9369; (b) A. G. Myers, E. Y. Kuo and N. S. Finney, J. Am. Chem. Soc., 1989, 111, 8057; (c) A. G. Myers and P. S. Dragovich, J. Am. Chem. Soc., 1989, 111, 9130.
- 4 (a) K. Toshima, O. Kazumi, A. Ohashi, T. Nakamura, M. Nakata, K. Tatsuta and S. Matsumura, J. Am. Chem. Soc., 1995, 117, 4822;

(b) K. C. Nicolaou, P. Maligres, J. Shin, E. de Leon and D. Rideout, J. Am. Chem. Soc., 1990, 112, 7825; (c) I. Saito, R. Nagata, H. Yamanaka and E. Okazaki, Tetrahedron Lett., 1989, 30, 4995; (d) I. Saito, R. Nagata, H. Yamanaka and E. Murahashi, Tetrahedron Lett., 1990, 31, 2907; (e) M. Shibuya, Y. Sakai, Y. Bando and K. Shishido, Tetrahedron Lett., 1992, 33, 957; (f) K. Morokuma and N. Koga, J. Am. Chem. Soc., 1991, 113, 1907; (g) K. Fujiwara, H. Sakai and M. Hirama, J. Org. Chem., 1991, 56, 1688.
5 (a) M.-J. Wu, C.-F. Lin, J.-S. Wu and H.-T. Chen, Tetrahedron

- 5 (a) M.-J. Wu, C.-F. Lin, J.-S. Wu and H.-T. Chen, *Tetrahedron Lett.*, 1994, **35**, 1879; (b) M.-J. Wu, C.-F. Lin and C.-W. Ong, *Bioorg. Med. Chem. Lett.*, 1996, **6**, 675; (c) M.-J. Wu, C.-F. Lin, H.-T. Chen, T.-H. Duh, S.-S. Wang and S.-C. Hsu, *Bioorg. Med. Chem. Lett.*, 1996, **6**, 2183; (d) W.-M. Dai, K. C. Fong, H. Danjo and S.-i Nishimoto, *Angew. Chem., Int. Ed. Engl.*, 1996, **35**, 779; (e) C.-F. Lin and M.-J. Wu, *J. Org. Chem.*, 1997, **62**, 4546.
- 6 For a review of cyclization of enyne-ketenes, see: H. W. Moore and B. R. Yerxa, *Chemtracts*, 1992, 273.
- 7 K. Nakatani, S. Isoe, S. Maekawa and I. Saito, *Tetrahedron Lett.*, 1994, 35, 605.
- 8 (a) C. Shi and K. K. Wang, J. Org. Chem., 1998, 63, 3517; (b) C. Shi, Q. Zhang and K. K. Wang, J. Org. Chem., 1999, 64, 925.
- 9 (a) K. K. Wang, Z. Wang and P. D. Sattsangi, J. Org. Chem., 1996, 61, 1516; (b) T. Gillmann, S. Heckhoff and T. Weeber, *Tetrahedron* Lett., 1996, 37, 839.
- 10 Some physical properties of **2**, **3**, **5**, **6** and **7**. **2**: ¹H NMR (CDCl₃, 200 MHz) δ 7.19–7.64 (m, 9H), 3.91 (s, 3H); ¹³C NMR (CDCl₃, 49.9 MHz) δ 134.8, 132.7, 132.6, 132.2, 130.5, 129.1, 128.3, 127.1, 126.8, 125.3, 117.4, 115.3, 92.4, 79.7, 60.4; MS (EI) m/z 249 (M⁺, 100%), 140 (85%) (HRMS (EI) calcd. for C₁₆H₁₁NS 249.0613. Found 249.0609). **3**: ¹H NMR (CDCl₃, 200 MHz) δ 8.07 (dd, 2H, J = 8.4, 1.4 Hz), 7.44–7.72 (m, 7H), 4.29 (s, 2H); ¹³C NMR (CDCl₃, 49.9 MHz) δ 137.8, 134.4, 133.0, 132.8, 132.4, 129.3, 129.2, 128.8, 125.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.3, 129.2, 128.8, 129.4, 129.4, 129.3, 129.2, 128.4, 129.4, 129.2, 128.4, 129.4, 117.0, 115.3, 83.5, 83.4, 49.3; MS (EI) m/z 281 (M⁺, 5%), 233 (7%), 140 (100%) (HRMS (EI) calcd. for C₁₆H₁₁NO₂S 281.0511. Found 281.0516). 4: ¹H NMR (CDCl₃, 400 MHz) δ 7.96 (d, 2H, J = 8.1 Hz), 7.51–7.69 (m, 6H), 7.35 (t, 1H, J = 7.6 Hz), 6.21 (s, 1H), 4.27 (s, 2H); MS (EI) m/z 299 (M⁺, 23%), 267 (36%), 158 (100%) (HRMS calcd. for C₁₆H₁₃NO₃S 299.0617. Found 299.0608). **5**: ¹H NMR (CDCl₃, 400 MHz) δ 8.21 (s, 1H), 7.93 (dd, 2H, J = 8.6, 1.1 Hz), 7.46–7.76 (m, 14H), 4.42 (s, 2H); MS (EI) *m*/*z*, 282 (M⁺ – C₆H₅SO₂), 218 (17), 141 (38), 77 (100) (HRMS calcd. for $C_{16}H_{12}NOS (M^+ - C_6H_5SO_2)$ 282.0590. Found 282.0590). **6**: ¹H NMR (CDCl₃, 400 MHz) δ 8.20 (dt, 1H, J = 7.9, 0.7 Hz), 7.86 (dt, 2H, J = 7.9, 0.7 Hz), 7.42–7.73 (m, 6H), 6.64 (s, 1H), 4.26 (d, 2H, J = 3.1 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 144.9, 138.3, 136.1, 135.1, 134.5, 129.7, 129.4, 129.2, 128.5, 128.4, 126.0, 120.7, 109.5, 29.7 (HRMS calcd. for $C_{16}H_{12}O_2N^{35}ClS$ 317.0279. Found 317.0266).

Communication 9/05509F